Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice

PURPOSE: Accumulating evidence suggests that not all cancer chemotherapy patients who receive first-cycle pegfilgrastim prophylaxis continue to receive it in subsequent cycles and that these patients may be subsequently at higher risk of febrile neutropenia (FN). Additional evidence from US clinical...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Support Care Cancer
Main Authors: Weycker, Derek, Li, Xiaoyan, Barron, Rich, Li, Yanli, Reiner, Maureen, Kartashov, Alex, Figueredo, Jacqueline, Tzivelekis, Spiros, Garcia, Jacob
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4846701/
https://ncbi.nlm.nih.gov/pubmed/26670915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-015-3039-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados